Status:
COMPLETED
Gynecomastia Extension Study
Lead Sponsor:
AstraZeneca
Conditions:
Gynecomastia
Eligibility:
MALE
11-18 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).
Eligibility Criteria
Inclusion
- Subjects must have entered Trial 1033US/0006 and completed 6 months of treatment and one month of follow-up.
- Subjects must have gynecomastia, with one breast measuring at least 3 cm in diameter.
Exclusion
- Subjects who have been given medications known to cause gynecomastia within the previous 3 months
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
End Date :
October 1 2002
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00637182
Start Date
January 1 2001
End Date
October 1 2002
Last Update
March 17 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.